app.rxdatalab.com · Free public feature

Regulatory filings linked to clinical programs and markets. Trials, SEC filings, insider activity, and market data from primary sources.

Get Full Access Today → Login →

BioHedge

Hedge fund positioning from Schedule 13D/13G filings. Each position cross-referenced with clinical trial events, regulatory filings, and insider trades. Free public view — the full platform adds company profiles, trial history, competitive landscape, and financing tracker for 500+ biotech companies.

Filings through Aug 14, 2026

Updated continuously

Weekly recaps → Strategic Signals → What are these? ↓

Activity Summary

Last 60 Days

New Positions

Increased

Decreased

Funds Active

Multi-Fund Activity

Companies with two or more institutional investors filing in the same period.

Accumulating

FULC Fulcrum Therapeutics, Inc.

▲5.6

5 funds

Nantahala Capital Management, LLC ▲8.2 , RA Capital Management ▼-9.9 , SUVRETTA CAPITAL MANAGEMENT, LLC ▼-3.9 , TANG CAPITAL MANAGEMENT LLC ▲2.2 , EcoR1 Capital ▲9.0

CLRB Cellectar Biosciences, Inc.

▲35.8

4 funds

SILVERARC CAPITAL MANAGEMENT, LLC ▲10.0 , StemPoint Capital LP ▲9.9 , Caligan Partners LP ▲5.9 , Empery Asset Management, LP ▲10.0

YARW Yarrow Bioscience, Inc.

▲28.8

4 funds

ADAR1 Capital Management, LLC ▲8.8 , Logos Global Management LP , OrbiMed ▲10.0 , Perceptive Advisors ▲10.0

NXTC NextCure, Inc.

▲15.8

4 funds

Squadron Capital Management LLC , ADAR1 Capital Management, LLC ▲15.8 , Ikarian Capital, LLC , Affinity Asset Advisors, LLC

KPRX KIORA PHARMACEUTICALS INC

▲10.0

3 funds

ADAR1 Capital Management, LLC , Nantahala Capital Management, LLC , Perceptive Advisors ▲10.0

Reducing

AVTX Avalo Therapeutics, Inc.

▼-5.8

8 funds

Deep Track Capital, LP ▲1.1, venBio Partners L.P. ▼-1.3, Caligan Partners LP ▼-1.3, RA Capital Management ▼-3.6, BVF Partners L.P. ▼-4.7, Nantahala Capital Management, LLC ▼-5.9, Affinity Asset Advisors, LLC, Commodore Capital LP ▲9.9

TENX TENAX THERAPEUTICS, INC.

▼-4.8

4 funds

RTW INVESTMENTS, LP, Perceptive Advisors ▼-1.0, BVF Partners L.P., Ikarian Capital, LLC ▼-3.8

SABS SAB BIOTHERAPEUTICS INC

▼-2.7

4 funds

Caligan Partners LP ▼-1.6, Commodore Capital LP, Perceptive Advisors ▼-1.1, RA Capital Management

CNTX Context Therapeutics Inc.

▼-14.9

3 funds

MPM BioImpact ▼-10.2, Blue Owl Capital Holdings LP ▼-2.4, Octagon Capital Advisors LP ▼-2.4

IKT INHIBIKASE THERAPEUTICS INC

▼-9.4

3 funds

Perceptive Advisors ▼-2.0, Nantahala Capital Management, LLC ▼-1.4, RA Capital Management ▼-6.0

Filing Volume by Week

13D 13G

Period:

Sort:

Filed	Fund	Company	Position	Gap
Aug 14, 2026 Event: 06/30/2026 Filed: Aug 14, 2026	G RTW INVESTMENTS, LP	RARE Ultragenyx Pharmaceutical Inc.	owns 7.9% NEW	—
G RTW INVESTMENTS, LP Aug 14, 2026 RARE Ultragenyx Pharmaceutical Inc. 7.9% NEW
Aug 14, 2026 Event: 06/30/2026 Filed: Aug 14, 2026	G RTW INVESTMENTS, LP	ORKA Oruka Therapeutics, Inc.	owns 5.2% NEW	178d
G RTW INVESTMENTS, LP Aug 14, 2026 ORKA Oruka Therapeutics, Inc. 5.2% NEW 178d
Aug 14, 2026 Event: 06/30/2026 Filed: Aug 14, 2026	G RTW INVESTMENTS, LP	QURE uniQure N.V.	owns 5.7% NEW	91d
G RTW INVESTMENTS, LP Aug 14, 2026 QURE uniQure N.V. 5.7% NEW 91d
Aug 14, 2026 Event: 06/30/2026 Filed: Aug 14, 2026	G RTW INVESTMENTS, LP	KLRA Kailera Therapeutics, Inc.	owns 8.3% NEW	—
G RTW INVESTMENTS, LP Aug 14, 2026 KLRA Kailera Therapeutics, Inc. 8.3% NEW
Aug 14, 2026 Event: 06/30/2026 Filed: Aug 14, 2026	G Deep Track Capital, LP	XFOR X4 Pharmaceuticals, Inc	owns 8.3% ▼-1.7	360d
G Deep Track Capital, LP Aug 14, 2026 XFOR X4 Pharmaceuticals, Inc 8.3% ▼-1.7 360d
Aug 14, 2026 Event: 06/30/2026 Filed: Aug 14, 2026	G GREAT POINT PARTNERS LLC	SCYNEXIS, Inc.	owns 10.0%	—
G GREAT POINT PARTNERS LLC Aug 14, 2026 SCYNEXIS, Inc. 10.0%
Aug 14, 2026 Event: 06/30/2026 Filed: Aug 14, 2026	G Deep Track Capital, LP	MBX MBX Biosciences	owns 3.6% ▼-2.9	365d
G Deep Track Capital, LP Aug 14, 2026 MBX MBX Biosciences 3.6% ▼-2.9 365d
Aug 14, 2026 Event: 06/30/2026 Filed: Aug 14, 2026	G venBio Partners L.P.	ARWR Arrowhead Pharmaceuticals Inc.	owns 9.6% ▲1.3	365d
G venBio Partners L.P. Aug 14, 2026 ARWR Arrowhead Pharmaceuticals Inc. 9.6% ▲1.3 365d
Aug 14, 2026 Event: 06/30/2026 Filed: Aug 14, 2026	G RTW INVESTMENTS, LP	SYRE Spyre Therapeutics, Inc.	owns 4.8% ▼-1.4	546d
G RTW INVESTMENTS, LP Aug 14, 2026 SYRE Spyre Therapeutics, Inc. 4.8% ▼-1.4 546d
Aug 14, 2026 Event: 06/30/2026 Filed: Aug 14, 2026	G RTW INVESTMENTS, LP	TENX TENAX THERAPEUTICS, INC.	owns 9.9%	91d
G RTW INVESTMENTS, LP Aug 14, 2026 TENX TENAX THERAPEUTICS, INC. 9.9% 91d

Understanding Schedule 13D and 13G Filings

Schedule 13D and 13G filings are SEC disclosures required when an investor acquires more than 5% of a company's outstanding shares.

Schedule 13D (Activist)

Filed when an investor may seek to influence management, board composition, or corporate strategy. Requires disclosure of investment purpose and plans.

Schedule 13G (Passive)

Filed by passive investors (mutual funds, index funds, institutions) with no intent to influence. Simpler filing requirements.

Gap column: Days since previous filing for the same fund+company pair.

Data source: SEC EDGAR. Filings typically available within 4 hours of submission.

This page reflects disclosed ownership changes only. Absence of activity does not imply absence of interest.

Intelligence Platform

Every event, in context.

Cross-reference each company's trial history, SEC filings, insider trades, and fund positioning in one view. Traceable to primary sources.

See the Platform → or email [email protected]